Melanoma Journal Articles for July 2017
Journal of Clinical Oncology
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin††, David Minor†, Sandra D’Angelo†, Bart Neyns†, Michael Smylie†, Wilson H. Miller†, …
DOI: 10.1200/JCO.2016.71.8023 Journal of Clinical Oncology – published online before print July 3, 2017
Anticancer Research
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide
KAVINDRA NATH, DAVID S. NELSON, JEFFREY ROMAN, MARY E. PUTT, SEUNG-CHEOL LEE, DENNIS B. LEEPER and JERRY D. GLICKSON
- Received May 10, 2017.
- Revision received May 24, 2017.
- Accepted May 25, 2017.
Anticancer Research July 2017 vol. 37 no. 73413-3421
Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma
Yasuhiro Nakamura, MD, PhD1; Yukiko Teramoto, MD, PhD1; Yuri Asami, MD1; et al
JAMA Dermatol. Published online July 5, 2017. doi:10.1001/jamadermatol.2017.1679
International Journal of Cancer
Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role?
Authors Edoardo Botteri1,2†* , Nathalie C. Støer1†, Solveig Sakshaug3 , Sidsel Graff-Iversen4 , Siri Vangen1,5, Solveig Hofvind6,7, Giske Ursin8,9,10, Elisabete Weiderpass11,12,13,14
Accepted online 7th July 2017
Perioperative BRAF inhibitors in locally advanced stage III melanoma.
Douglas Zippel MD, Gal Markel MD, Roni Shapira-Frommer MD, Guy Ben-Betzalel MD, David Goitein MD, Eytan Ben-Ami MD, Aviram Nissan MD, Jacob Schachter MD, Schlomo Schneebaum MD
First published: 26 June 2017
J. Surg. Oncol.http://dx.doi.org/10.1002/jso.24744(2017)
Neadjuvant BRAF inhibition enables resection
Nature Reviews Clinical Oncology (2017)
doi:10.1038/nrclinonc.2017.106
Published online 11 July 2017
Int. J. Mol. Sci. 2017, 18(7), 1508; doi: 10.3390/ijms18071508
Article
Cudraflavone C Induces Apoptosis of A375.S2 Melanoma Cells through Mitochondrial ROS Production and MAPK Activation
Chiang-Wen Lee 1,2,3,†, Feng-Lin Yen 4,5,†, Horng-Huey Ko 4, Shu-Yu Li 6, Yao-Chang Chiang 1,7, Ming-Hsueh Lee 8, Ming-Horng Tsai 9 and Lee-Fen Hsu 10,*
Received: 14 June 2017 / Accepted: 6 July 2017 / Published: 13 July 2017
International Journal of Molecular Sciences
Review Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
Xian Yang Chan, Alamdeep Singh, Narin Osman and Terrence J. Piva
Received: 19 June 2017; Accepted: 12 July 2017; Published: 14 July 2017
Oncology Letters
Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
Xiaowen Wu, Junya Yan, Jie Dai, Meng Ma, Huan Tang, Jiayi Yu, Tianxiao Xu, Huan Yu, Lu Si, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jun Guo
Published online on: July 19, 2017 https://doi.org/10.3892/ol.2017.6608
Oncology Reports
Clinical significance of miR-138 in patients with malignant melanoma through targeting of PDK1 in the PI3K/AKT autophagy signaling pathway
Fanjun Meng, Yuxia Zhang, Xing Li, Juan Wang, Zhiyu Wang
Published online on: July 19, 2017 https://doi.org/10.3892/or.2017.5838
Clinical Cancer Research
PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors
Hojabr Kakavand, Robert V Rawson, Gulietta M Pupo, Jean Y H Yang, Alexander M Menzies, Matteo S. Carlino, Richard F. Kefford, Julie R Howle, Robyn Saw, John F. Thompson, James S Wilmott, Georgina V. Long, Richard A. Scolyer and Helen Rizos
DOI: 10.1158/1078-0432.CCR-16-1688 Published January 2017
JAMA Dermatology
Research Letter
July 26, 2017
Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy
Jérôme Doyen, MD, PhD1; Alexandra Picard, MD2; Arash O. Naghavi, MD3; et alAntoine Thyss, MD4; Thierry Passeron, MD, PhD2; Jean-Philippe Lacour, MD, PhD2; Henri Montaudié, MD2
JAMA Dermatol. Published online July 26, 2017. doi:10.1001/jamadermatol.2017.2222
JAMA Dermatology
Original Investigation
July 26, 2017
Risk Factors for Melanoma in Renal Transplant Recipients
Mona Ascha, MD1,2; Mustafa S. Ascha, BS, MS3; Joseph Tanenbaum, BA1; et alJeremy S. Bordeaux, MD, MPH4
JAMA Dermatol. Published online July 26, 2017. doi:10.1001/jamadermatol.2017.2291
JAMA Dermatology
Brief Report
July 26, 2017
Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma
Steven Vernali, BA1; Weston T. Waxweiler, MD1; Patrick M. Dillon, MD2; et alPeter A. Kanetsky, MPH, PhD3; Irene Orlow, PhD4; Li Luo, PhD5; Klaus J. Busam, MD4; Anne Kricker, PhD6; Bruce K. Armstrong, MBBS, DPhil6; Hoda Anton-Culver, PhD7; Stephen B. Gruber, MD, MPH, PhD8; Richard P. Gallagher, MA9; Roberto Zanetti, MD10; Stefano Rosso, MD, MSc10; Lidia Sacchetto, MSc10,11,12; Terence Dwyer, MD13; Anne E. Cust, PhD6; David W. Ollila, MD14,15; Colin B. Begg, PhD4; Marianne Berwick, MPH, PhD5; Nancy E. Thomas, MD, PhD1,14; for the GEM Study Group
JAMA Dermatol. Published online July 26, 2017. doi:10.1001/jamadermatol.2017.2444
International Journal of Oncology
Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF??B pathway
Biao Zhang, Jing Zhang, Jingxuan Pan
Published online on: July 25, 2017 https://doi.org/10.3892/ijo.2017.4079